Expand all sections

Durvalumab

Imfinzi

Extended indication

Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresect

Therapeutic value

No estimate possible yet
Registration phase

Positive CHMP opinion

Product

Active substance

Durvalumab
Domain

Oncology
Reason of inclusion

Indication extension
Main indication

Liver cancer
Extended indication

Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
Proprietary name

Imfinzi
Manufacturer

AstraZeneca
Mechanism of action

PD-1 / PD-L1 inhibitor
Route of administration

Intravenous
Therapeutical formulation

Intravenous drip
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
Submission date

2023
Expected Registration

December 2023
Registration phase

Positive CHMP opinion
Additional remarks 
Posititve CHMP-opinie oktober 2023

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.